Lobbying Filing Details

Total Spending

$40,000

Activities

5

Lobbyists

5

Gov't Entities

10

Filing Information
Filing UUID:
271f4e33-4030-44c9-b57f-47b92f3c25c7
Type:
Q1 - 1st Quarter - Report
Period:
2026 - 1st Quarter (Jan 1 - Mar 31)
Date Posted:
April 20, 2026 at 8:26 PM
Income:
$40,000
Expenses:
$0
Document URL:
View Submission
Quick Info
  • Document Type: text/html
  • Posted By: Mathew Lapinski
Registrant
CROSSROADS STRATEGIES, LLC

lobbying firm

Washington, District of Columbia
Client
MERCK & CO., INC.

developer, manufacturer and distributor of pharmaceuticals

District of Columbia, United States of America
Lobbying Activities (5)
Activity 1
Copyright/Patent/Trademark

Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.

Lobbyists (5)
  • MATHEW LAPINSKI
  • JASON BENJAMIN VAN PELT
  • BRITTANY JOHNSON HERNANDEZ
  • MS. CHERYL LYNN JAEGER
  • MR. STEPHEN THOMAS VOLJAVEC
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 2
Health Issues

Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2027 National Defense Authorization Act), antimicrobial resistance, VICP Program, PBM reform, vaccine schedule and vaccine safety; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

Lobbyists (5)
  • MATHEW LAPINSKI
  • JASON BENJAMIN VAN PELT
  • BRITTANY JOHNSON HERNANDEZ
  • MS. CHERYL LYNN JAEGER
  • MR. STEPHEN THOMAS VOLJAVEC
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 3
Medicare/Medicaid

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.

Lobbyists (5)
  • MATHEW LAPINSKI
  • JASON BENJAMIN VAN PELT
  • BRITTANY JOHNSON HERNANDEZ
  • MS. CHERYL LYNN JAEGER
  • MR. STEPHEN THOMAS VOLJAVEC
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 4
Taxation/Internal Revenue Code

Issues related to tax reform; R&D tax credit; international taxation; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.

Lobbyists (5)
  • MATHEW LAPINSKI
  • JASON BENJAMIN VAN PELT
  • BRITTANY JOHNSON HERNANDEZ
  • MS. CHERYL LYNN JAEGER
  • MR. STEPHEN THOMAS VOLJAVEC
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 5
Trade (domestic/foreign)

Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals.

Lobbyists (5)
  • MATHEW LAPINSKI
  • JASON BENJAMIN VAN PELT
  • BRITTANY JOHNSON HERNANDEZ
  • MS. CHERYL LYNN JAEGER
  • MR. STEPHEN THOMAS VOLJAVEC
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES

Source: LDA.gov, data retrieved November 10, 2026. FilingExplorer is not affiliated with LDA.gov; the Senate Office of Public Records cannot vouch for data or analyses derived from these records after retrieval.